Compare BIO-TECHNE Corp (TECH) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Direxion Daily TSLA Bull 2X Shares — how do they compare? BIO-TECHNE Corp trades at $72.18 (market cap $11.24B), while Direxion Daily TSLA Bull 2X Shares trades at $8.26. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while Direxion Daily TSLA Bull 2X Shares pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| TECH | TSLL | |
|---|---|---|
Market Cap | $11.24B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $72.29 | $23.03 |
52-Week Low | $43.31 | $6.74 |
Enterprise Value | $11.32B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
TSLL, the Direxion Daily TSLA Bull 2X Shares ETF, trades at $8.11, up 5.6% today. Technical indicators show a mixed picture with a bullish overall signal but bearish moving averages. The ETF, which aims to deliver twice Tesla's daily returns, lacks fundamental metrics as it is a leveraged product. Recent news highlights its volatility and investor focus on Tesla's performance.
The outlook for TSLL is tied to Tesla's stock volatility, offering amplified gains but significant risks. Key opportunities include potential upside from Tesla's growth, while risks involve high volatility and decay from daily rebalancing. Investors should be cautious due to the leveraged structure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
